This study is an exploratory, multicenter, single-group clinical trial aimed to evaluate the clinical outcomes of using ShockPulse-10 in the treatment of coronary artery calcification .
The study will be conducted at 8 sites in China and up to 205 participants will be followed for 180 days post procedure. Patients ≥18 years of age scheduled for stent procedure with evidence of significant calcified stenosis of left main, or left anterior descending, right coronary artery or left circumflex will be eligible to enroll in the study. The primary endpoint of the study will evaluate procedure success,procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
205
Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians
Beijing Anzhen Hosipital
Beijing, Beijing Municipality, China
RECRUITINGProcedure success
Procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization
Time frame: immediately post-procedure or prior to discharge, whichever comes first
Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure
Freedom from major adverse cardiac events (MACE) within 30(±7days) days of the index procedure;MACE is defined as:Cardiac death; or Myocardial Infarction (MI): or Target Vessel Revascularization
Time frame: 30(±7days)days post index procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.